Mechanism of Action at Cellular and Tissue Levels
The pharmacological action of somatropin is based on the precise replication of the physiological processes of endogenous growth hormone. As a recombinant analogue, the drug shares an identical amino acid sequence, allowing it to seamlessly integrate into endocrine regulation.
The mechanism of action unfolds in several sequential stages:
- Cellular Level: Upon administration, the drug molecules reach target cells and bind to specific cell-surface receptors. This binding acts as a trigger that activates intracellular enzyme systems, notably the mitogen-activated protein kinase (MAPK) pathway.
- Tissue Level: Driven by activated intracellular cascades, peripheral tissues begin to actively synthesize somatomedins.
- Effector Level: Among all somatomedins, insulin-like growth factor (IGF) plays a key role. In modern pharmacology, IGF is considered the primary mediator through which the ultimate anabolic action of the drug is executed. The hormone itself acts merely as the initiator, whereas IGF performs the bulk of the work in stimulating cell division.
Pharmacodynamic Effects and Metabolic Impact
The systemic effects of the drug impact fundamental metabolic processes. The primary pharmacodynamic effect is a pronounced enhancement of tissue growth. Bone and skeletal muscle tissues are most sensitive to the drug, responding with an active increase in mass and linear dimensions.
To support such intensive growth, the drug profoundly shifts metabolism toward anabolism:
- Protein Metabolism: Powerful activation of protein synthesis occurs, representing a classic manifestation of anabolic activity required for the formation of new cellular structures.
- Mineral Metabolism: The drug promotes the retention of critical macroelements in the body, reducing urinary excretion of phosphorus and calcium, which are essential for the mineralization of growing bone tissue.
- Nitrogen Balance: A marked nitrogen retention is observed, serving as a direct marker of protein synthesis exceeding protein breakdown.
- Fluid-Electrolyte Balance: The drug decreases sodium excretion, contributing to fluid retention in the body.
Clinical Application and Safety Profile
The primary therapeutic target for somatropin is growth failure and dwarfism. The drug is successfully used to correct delayed physical development, including complex genetic pathologies such as Turner syndrome.
Despite high clinical efficacy, the use of recombinant growth hormone is associated with several adverse effects that logically stem from its pharmacodynamics:
- Carbohydrate Metabolism: The drug exhibits significant counter-regulatory (anti-insulin) activity. By counteracting insulin effects, it can cause hyperglycemia (elevated blood glucose levels).
- Fluid Retention: Due to decreased urinary sodium excretion, patients frequently develop edema.
- General Symptoms: Nonspecific reactions such as headaches and marked fatigue may occur during therapy.
Particular attention is paid to clinical contraindications. Somatropin is strictly contraindicated in patients with malignant neoplasms. Because the drug and its mediator IGF are potent stimulators of cell division, there is a critical risk of accelerating the growth of an existing tumor.
Other Anterior Pituitary Hormones
In addition to growth hormone, the anterior pituitary secretes several other key regulators. The pharmaceutical industry manufactures thyrotropin (TSH) and prolactin (lactogenic hormone). However, unlike somatropin, these agents have extremely narrow indications and are not widely used in general medical practice today.